Creative Commons License

Borlu M.

TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, vol.56, pp.58-60, 2022 (ESCI) identifier identifier


Brodalumab is a human monoclonal antibody that inhibits interleukin-17 (IL-17) pathway by binding to IL-17 receptor. In clinical trials, a PASI75 response has been achieved in 82-84% of the patients at week 12. It was shown to be effective also in generalized pustular and erythrodermic psoriasis. As with other IL-17 inhibitors, brodalumab should be used with caution in patients with inflammatory bowel disease.